Clinical trial
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic…
NCT00082914 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00082914 |
|---|---|
| Title | Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer |
| Official title | Phase II Evaluation of Denileukin Diftitox in Patients With Metastatic Melanoma or Metastatic Kidney Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | denileukin diftitox |
| Start date | Mar 1, 2004 |
| Completion | Jul 1, 2006 |
| First posted | May 19, 2004 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: